Orthostatic Hypotension and Mortality in Elderly Frail Patients

A Retrospective Cross-Sectional Study

Tamar Freud, PhD, Boris Punchik, MD, and Press Yan, MD

Abstract: Orthostatic hypotension (OH) is a common problem in the elderly age group, and some studies have reported an association between OH and increased mortality. We evaluated possible associations between OH and mortality in a retrospective study of frail elderly patients who came for a comprehensive geriatric assessment.

The study included all patients ≥65 years who were assessed in the outpatient Comprehensive Geriatric Assessment Unit. Data were collected from the computerized medical record, including blood pressure, sociodemographic data, lifestyle, falls, pulse rate, body mass index, functional and cognitive status, and comorbidity. Data on mortality were also collected.

The study population consisted of 571 patients who underwent assessment over a 9-year study period. The mean age was 83.7 ± 6.1, 35.9% were males, and 183 (32.1%) were diagnosed with OH. Systolic OH (OHS) was more common than diastolic OH (25.2% vs 15.6%). In univariate analyses, OHS was associated with increased overall mortality. Over the follow-up period, 30.2% of the OHS patients died compared with 22.3% (P = 0.037), but in the Cox models there was no statistically significant associations between OHS and overall mortality. In contrast, age, burden of comorbidity, a low high-density lipoprotein level, and low creatinine clearance were independent predictors of increased overall mortality.

In a population of frail elderly patients with a high burden of comorbidity, OH was not an independent risk factor for overall mortality.

(Medicine 94(24):e977)

INTRODUCTION

The prevalence of orthostatic hypotension (OH) in elderly populations ranges from 6.9%1 to 55.2%2 with variations related mostly to the method of measurement and the study population.

Associations have been found between OH and medical conditions, including syncope,1 falls,3,4 cardiac events,5,6 atrial fibrillation (AF),7,8 heart failure,9,10 and stroke.11 Several studies conducted in different populations have investigated possible associations between OH and mortality. In 2 systematic reviews with meta-analyses,12,13 the investigators found an increase in overall mortality in patients with OH. However, even in these reviews, there is a variance in studies conducted in different populations.

The aim of the present study was to assess a possible association between the presence of OH and overall mortality among elderly patients who underwent a comprehensive geriatric evaluation in the Comprehensive Geriatric Assessment Unit (CGAU).

METHODS

Study Population

The CGAU of the Clalit Health Services in Beer-Sheva was established in 2004. The unit has been described in an earlier publication.14 In short, the unit conducts comprehensive geriatric assessments for frail elderly community-dwelling individuals. The unit’s staff include geriatricians, a nurse, a social worker, and a secretary. It also has the part-time services of an occupational therapist, a physical therapist, and a dietitian. The unit functions up to 15 h/week and serves patients ≥65 years who are insured by the Clalit Health Services (approximately 25,000 individuals). Patients who come to the CGAU for a comprehensive geriatric assessment undergo a 5 to 6-hour evaluation that includes physical, functional, cognitive, affective, social, and environmental examinations. In the course of the assessment, the patients undergo supine and upright blood pressure measurements to identify OH.

The study population was composed of patients who underwent this comprehensive assessment at the CGAU over the course of 9 years between January 2005 and December 2013 and who had 3 recorded blood pressure measurements that enabled the investigators to calculate orthostatic blood pressure changes.

Resources and Service Instrumental Activity of Daily Living. OH = orthostatic hypotension, OHD = diastolic orthostatic hypotension, OHN = orthostatic hypotension negative, OHP = orthostatic hypotension positive, OHS = systolic orthostatic hypotension.

Abbreviations: AF = atrial fibrillations, BI = Barthel Index, BMI = body mass index, CCI = Charlson Comorbidity Index, CGAU = Comprehensive Geriatric Assessment Unit, CHF = congestive heart failure, CVA = cerebrovascular accident, DM = diabetes mellitus, HDL-C = high-density lipoprotein-cholesterol, HR = hazard ratio, HTN = hypertension, IHD = ischemic heart disease, MMSE = Minimental State Examination, OARS-IADL = Older Americans Resources and Service Instrumental Activity of Daily Living.
Blood Pressure Measurements

Blood pressure measurements were taken routinely for all patients who came to the CGAU for a comprehensive geriatric assessment and who were able to lie down for 10 minutes and stand up for 3 minutes. All measurements were done during the unit’s working hours between 8 am and 4 pm. Throughout 9 years of the study, the measurements were taken by the same nurse using the same protocol with an electronic instrument (Automatic Scholar III EL Monitor, Criticare Systems, Inc).

The blood pressure cuff device was adjusted to the patient’s arm with the patient lying down flat with their hands along the body axis. After the patient lay down for 10 minutes, blood pressure was measured and the patient was asked to stand up. The first standing blood pressure measurement was then taken within 1 minute of standing and was repeated at the third minute of standing.

Definitions of OH

In our usual practice, we use the definitions of the Consensus Statement on the Definition of Orthostatic Hypotension,15 published in 1996. According to these definitions, OH is diagnosed as a drop in systolic blood pressure of at least 20 mm Hg or in diastolic blood pressure of at least 10 mm Hg within 3 minutes of standing. For the purposes of the present study, we used the following diagnostic criteria:

1. Systolic OH at the first minute of standing (OHS1)—a drop in systolic blood pressure of ≥20 mm Hg at the first minute upright compared to the measurement at the 10th minute supine.
2. Systolic OH at the third minute of standing (OHS3)—a drop in systolic blood pressure of ≥20 mm Hg at the third minute upright compared to the measurement at the 10th minute supine.
3. “Any OHS”—a drop in systolic blood pressure of ≥20 mm Hg at the first and/or the third minute upright compared to the measurement at the 10th minute supine.
4. Diastolic OH at the first minute upright (OHD1)—a drop in diastolic blood pressure of ≥10 mm Hg at the first minute upright compared to the measurement at the 10th minute supine.
5. Diastolic OH at the third minute upright (OHD3)—a drop in diastolic blood pressure of ≥10 mm Hg at the third minute upright compared to the measurement at the 10th minute supine.
6. “Any OHD”—a drop in diastolic blood pressure of ≥10 mm Hg at the first and/or the third minute upright compared to the measurement at the 10th minute supine.
7. Orthostatic hypotension positive (OHP)—“Any OHS” and/or “Any OHD.”
8. Orthostatic hypotension negative (OHN)—there was no evidence for either systolic or diastolic OH at the first or third minute upright.

Data Collection

All measurements were recorded and stored in a computer program that was designed specifically for the CGAU. The computerized record contains sociodemographic data, life habits, falls, blood pressure, pulse rate, weight, height, Minimal State Examination (MMSE),16 the Older Americans Resources and Service Instrumental Activity of Daily Living (OARS-IADL),17 the Barthel Index (BI),18 chronic diseases list, and comorbidity indices including the Charlson Comorbidity Index (CCI).19 For the present study, we chose to use the CCI because its authors designed it primarily as a predictor of mortality. This index is a summation score of points given for comorbidity (TS—total score) and points given for age (age score). For the present study, we used only the total score (CCI-TS) to separate the effect of comorbidity from the effect of age. Details on recent laboratory tests taken just before the assessment at the CGAU were obtained from the patients’ computerized medical records. Information on medications during the assessment at the CGAU was obtained from the pharmacological data system including all drugs that were supplied through prescriptions over the 3 months before the assessment. Information on dates of death was obtained from the data systems of the Clalit Health Services and included data up to February 15, 2014. The data related to the overall mortality only, without cause of death.

Statistical Analysis

The results are reported as mean ± standard deviation. The unadjusted mortality rate, expressed per 100 person-years, was calculated according to OH status as follows: (Total number of deaths × 100/number of participants)/mean follow-up period to death/year of study completion.

The survival of OH and non-OH patients was compared using the Cox proportional hazard regression model, adjusting for additional factors such as age, sex, body mass index (BMI), MMSE, BI, OARS-IADL, number of drugs with OH potential, ischemic heart disease (IHD), AFs, congestive heart failure (CHF), total cholesterol, and high-density lipoprotein cholesterol (HDL-C). The results are presented as hazard ratios (HRs) and 95% confidence intervals (CIs). Continuous variables were compared using the Student t test and analysis of variance, and categorical variables using the χ² test. The study was approved by the ethics committee of the Meir Hospital in Kfar Saba, Israel.

RESULTS

Over the course of the study, 628 patients underwent geriatric assessment at the CGAU. Of these, 571 (90.9%) had blood measurements that enabled OH calculations and were included in the analysis. There were no significant differences between patients included in the analysis and those who were not in terms of age, sex, or overall mortality.

The mean age of the study population was 83.7 ± 6.1 and 35.9% were males. OHP was found in 183 patients (32.1%). Any OH was more common than Any OHD (25.3% vs 15.6%); And OHS1 was more common than OHS3 (23.8% vs 8.6%).

Mortality Rates

In all, 212 of the 571 patients (37.1%) died over a follow-up period of 4.2 ± 2.6 years (range 0.02–9.0). There were no statistically significant differences in mortality rates between patients with any type of OH and those without OH. The unadjusted mortality rate among patients with OHP was 9.6/100 person-years compared with 8.5 among patients with OHN (Risk Ratio = 1.13; 95% CI: 0.85–1.50). There was no difference between these 2 groups in the mean follow-up period to death, which was 3.5 years. The unadjusted mortality rate per 100 person-years was 11.0 among patients with OHS1 compared...
| Comparison of Nonsurvivors and Survivors | Nonsurvivors N = 212 | Survivors (N = 359) | P  |
|----------------------------------------|-----------------------|----------------------|----|
| Any OHS, N (%)                         |                       |                      |    |
| Yes                                    | 64 (30.2)             | 80 (22.3)            | 0.037 |
| No                                     | 148 (69.8)            | 279 (77.7)           |    |
| Any OHD, N (%)                         |                       |                      |    |
| Yes                                    | 34 (16.0)             | 55 (15.3)            | 0.812 |
| No                                     | 178 (84.0)            | 304 (84.7)           |    |
| OH, N (%)                              |                       |                      |    |
| OHP                                    | 75 (35.4)             | 108 (30.1)           | 0.195 |
| OHN                                    | 137 (64.6)            | 251 (69.9)           |    |
| Sex, N (%)                             |                       |                      |    |
| Male                                   | 98 (46.2)             | 107 (29.8)           | <0.0001 |
| Female                                 | 114 (53.8)            | 252 (70.2)           |    |
| Age                                    |                       |                      |    |
| Mean ± SD                              | 86.1 ± 6.3            | 82.3 ± 5.5           | <0.0001 |
| Range                                  | 67–103                | 67–97                |    |
| Falls in the past, %                   | 81.8                  | 83.4                 | 0.639 |
| Number of falls in past                |                       |                      |    |
| Mean ± SD                              | 3.8 ± 6.3             | 3.8 ± 8.0            | 0.999 |
| Range                                  | 0–50                  | 0–52                 |    |
| BMI                                    |                       |                      |    |
| Mean ± SD                              | 27.6 ± 5.2            | 28.9 ± 5.2           | 0.006 |
| Range                                  | 14.9–46.4             | 16.0 ± 44.2          |    |
| BI                                     |                       |                      |    |
| Mean ± SD                              | 79.0 ± 17.6           | 87.2 ± 14.4          | <0.001 |
| Range                                  | 25–100                | 35–100               |    |
| IADL                                   |                       |                      |    |
| Mean ± SD                              | 6.33 ± 3.3            | 8.4 ± 3.4            | <0.001 |
| Range                                  | 0–14                  | 0–14                 |    |
| MMSE                                   |                       |                      |    |
| Mean ± SD                              | 20.8 ± 2.7            | 22.6 ± 5.4           | <0.001 |
| Range                                  | 2–30                  | 6–30                 |    |
| Total Charlson score                   |                       |                      |    |
| Mean ± SD                              | 2.9 ± 2.05            | 1.85 ± 1.6           | <0.001 |
| Range                                  | 0–11                  | 0–8                  |    |
| Comorbidity, N (%)                     |                       |                      |    |
| HTN                                    | 167 (78.8)            | 274 (76.3)           | 0.386 |
| IHD                                    | 88 (41.5)             | 114 (31.8)           | 0.017 |
| AF                                     | 32 (15.1)             | 35 (9.7)             | 0.058 |
| DM                                     | 92 (43.4)             | 138 (38.4)           | 0.212 |
| CVA                                    | 40 (18.9)             | 58 (16.2)            | 0.420 |
| CHF                                    | 39 (18.4)             | 31 (8.6)             | 0.001 |
| COPD                                   | 17 (8.0)              | 29 (8.1)             | 1.000 |
| Cancer                                 | 18 (8.5)              | 18 (5.0)             | 0.108 |
| Parkinson                              | 20 (9.4)              | 20 (5.6)             | 0.089 |
| Number of medications/month           |                       |                      |    |
| Mean ± SD                              | 8.4 ± 4.7             | 8.0 ± 4.1            | 0.305 |
| Range                                  | 0.7–29.7              | 1.0–23.7             |    |
| Total cholesterol                      |                       |                      |    |
| Mean ± SD                              | 179.0 ± 40.1          | 186.9 ± 44.4         | 0.039 |
| Range                                  | 78–285                | 90–377               |    |
| LDL-C                                  |                       |                      |    |
| Mean ± SD                              | 99.5 ± 31.6           | 105.3 ± 37.6         | 0.067 |
| Range                                  | 30–193                | 38–264               |    |
| HDL-C                                  |                       |                      |    |
| Mean ± SD                              | 52.7 ± 15.2           | 55.5 ± 14.7          | 0.038 |
| Range                                  | 19–99                 | 28–113               |    |
| Hemoglobin                             |                       |                      |    |
| Mean ± SD                              | 12.9 ± 1.5            | 13.1 ± 1.3           | 0.189 |
| Range                                  | 9–17                  | 9–17                 |    |
with 10.7 for patients with Any OHS, 9.0 for OHD1, and 9.1 for Any OHD.

Table 1 shows the characteristics of patients who survived compared to those who died. The survivors were significantly younger, more were females, their BMI was higher, their basic and instrumental activity of daily living was lower, and their MMSE score was lower. The burden of illness, measured by CCI, including IHD and CHF was higher among the deceased. Survivors had higher levels of creatinine clearance, total cholesterol, and HDL. There were no significant differences between survivors and deceased in the rate of falls in the past, the number of drugs, the low-density lipoprotein level, and hemoglobin concentration. There were also no significant differences between survivors and deceased in essential hypertension (HTN), diabetes mellitus (DM), cerebral vascular accident (CVA), chronic obstructive pulmonary disease, Parkinson disease, and malignancy. There was a trend to higher rates of AF among the deceased.

**TABLE 2. Multivariate Cox Proportional Hazards Analysis**

| Variable                              | Hazard Ratio | 95% CI          | P      |
|---------------------------------------|--------------|-----------------|--------|
| Age, y                                | 1.057        | 1.030–1.085     | <0.0001|
| Sex (male)                            | 1.405        | 1.022–1.931     | 0.036  |
| BMI                                   | 0.946        | 0.916–0.977     | 0.001  |
| MMSE                                  | 1.002        | 0.975–1.029     | 0.901  |
| BI                                    | 1.000        | 0.987–1.013     | 0.964  |
| OARS-IADL                             | 0.942        | 0.882–1.007     | 0.08   |
| Number of drugs with OH potential     | 1.007        | 0.915–1.108     | 0.89   |
| Any OHS (yes/no)                      | 1.052        | 0.751–1.473     | 0.768  |
| CCI-TS                                | 1.212        | 1.108–1.326     | <0.0001|

**BI** = Barthel Index, **BMI** = body mass index, **CCI-TS** = Charlson Comorbidity Index total score, **MMSE** = Minimential State Examination, **OARS-IADL** = Older Americans Resources and Service Instrumental Activity of Daily Living, **OH** = orthostatic hypotension, **OHS** = systolic orthostatic hypotension.

**DISCUSSION**

In this retrospective study conducted in a frail elderly population seen at the outpatient CGAU, OH was not associated with an increase in overall mortality. This result contradicts the results of earlier published studies on this issue, in which the investigators found that patients with OH had increased overall mortality ranging from 16% to 71%. However, some previous studies also did not find an association between OH and overall mortality. Xin et al reported that associations between overall mortality and OH were less
TABLE 3. Multivariate Cox Proportional Hazards Analysis

| Variable                      | Hazard Ratio | 95% CI      | P     |
|-------------------------------|--------------|-------------|-------|
| Age, y                        | 1.032        | 1.000–1.065 | 0.049 |
| Sex (male)                    | 1.291        | 0.931–1.790 | 0.125 |
| BMI                           | 0.972        | 0.936–1.009 | 0.133 |
| M convergence                  | 0.991        | 0.964–1.018 | 0.498 |
| BI                            | 0.988        | 0.976–1.000 | 0.055 |
| OARS-IADL                      | 0.971        | 0.909–1.036 | 0.373 |
| Number of drugs with OH potential | 0.951    | 0.857–1.056 | 0.344 |
| IHD                           | 1.159        | 0.821–1.638 | 0.402 |
| AF                            | 1.342        | 0.883–2.039 | 0.168 |
| CHF                           | 1.465        | 0.957–2.242 | 0.079 |
| Any OHS (yes/no)              | 1.178        | 0.846–1.641 | 0.333 |
| Total Cholesterol             | 0.997        | 0.993–1.002 | 0.234 |
| HDL-C                         | 0.988        | 0.977–1.000 | 0.048 |
| Creatinine clearance          | 0.985        | 0.985–0.997 | 0.015 |

AF = atrial fibrillations, BI = Barthel Index, BMI = body mass index, CHF = congestive heart failure, OHS = systolic orthostatic hypotension, HDL-C = high-density lipoprotein cholesterol, IHD = ischemic heart disease, MMSE = Minimental State Examination, OARS-IADL = Older Americans Resources and Service Instrumental Activity of Daily Living, OH = orthostatic hypotension.

striking in retrospective studies, studies that were not community based, and studies in which the prevalence of OH was >20%. Furthermore, the association between overall mortality and OH was less significant in studies in which adjustments were made for “classic” risk factors for cardiovascular disease.

In another retrospective study conducted by Largo et al,25 following adjustment for other risk factors, the statistically significant association between overall morality and OH was no longer found. The present study is based on data for CGAU patients, who are similar to hospitalized patients or patients in a tertiary clinic rather than a community-based clinic. Other studies that did not find an association between overall mortality and OH were also conducted in atypical populations. Weiss et al24 evaluated patients who were discharged following acute hospitalizations in the Department of Geriatrics; Largo et al22 evaluated patients at the falls clinic; and Fisher et al23 studied patients from long-term health care facilities. The prevalence of OH in the present study was 32.1%. This is high in relation to studies that found a significant association between overall mortality and OH.13 Federowski et al20 reported a prevalence of 4.1% for OHS and 2.4% for OH; Masaki et al1 reported a prevalence of 6.9% for OH, the prevalence of OH in the ARIC study was 5.1%; and Verwoert et al22 found a prevalence rate of 17.8% for OH. In contrast, in studies that did not find a significant association between overall mortality and OH the prevalence of OH ranged from 23% in the study by Fisher et al23 to 54% in the study by Largo et al.25 It should be noted that in the study by Luukinen et al,20 in which the prevalence of OH was 30%, there was no increase in nonvascular death among patients with OH, but the rate of vascular death in this group was higher, especially among patients with DM.22 In light of the limitations of the present study (absence of reliable data in the medical record on causes of mortality), we were not able to assess specific causes of death.

The mortality rate for patients in the present study was 10.6 per 100 person-years. In those studies, in which OH was found to be a predictor of overall mortality, the mortality rate was much lower with Fedorowski et al reporting 0.9 per 100 person-years,6 Rose et al 1.0,21 and Masaki et al 3.4,1 Verwoert et al22 reported the highest mortality rate of 4.7 per 100 person-years. In contrast, in studies in which no association was found between overall mortality and OH, the mortality rate was higher: 9.3,25 11.6,23 and 15.3.24

The differences in mortality among the studies are probably related to age and burden of disease. In the present study, the mean age was 83.7. In studies that found a significant association between mortality and OH, the mean age of the patients was younger: 45.7 in the study by Fedorowski et al,6 54.0 in the study by Rose et al,21 and 68.1 in the study by Verwoert et al.22 The only study with a significant association and a more elderly population was the study by Masaki et al1 where the age range was 71 to 93 years.

In studies where no significant association was found between mortality and OH the mean age of the patients was higher: 78.8 in the study by Largo et al,25 81.5 in the study by Weiss et al,24 and 83.2 in the study by Fisher et al.23 In the study by Luukinen et al,20 in which the authors found an increase in vascular mortality but not in nonvascular mortality, the mean age was 74.0. Fedorowski et al6 found a weaker effect of OH on mortality with increase in age. In patients <42 and 48 years of age, the adjusted HR was 1.46; in those between 42 and 28 years of age, it was 1.21; and in those ≥48 years, it was 1.17. Similarly, in the study by Rose et al,21 the HR for OH as a predictor of overall mortality in younger patients was 3.7 compared to 1.6 in older patients (60–65 years).

Morbidity is another factor that can explain the differences in mortality among the various studies. In comparison with studies that found a significant association between overall mortality and OH, patients in studies that did not find this association had higher rates of chronic morbidity. Thus, in studies with patients in relatively similar age ranges, but with contradictory results, such as Weiss et al24 and Masaki et al,1 there was a significant difference in burden of disease. In the study by Weiss et al, in which there was no significant association between mortality and OH, the prevalence of DM, HTN, coronary heart disease, and CVA was higher than in the study by Masaki et al where there was a significant association. This difference can be explained, at least in part, by the study setting, that is, community-based versus geriatrics ward, but the authors themselves suggested that the low morbidity rates among the
patients stemmed from genetic and ethnic factors.\(^6\) Weiss et al\(^{24}\) contended that the lack of association between overall mortality and OH in their study can be explained, in part, by the fact that their patient population, which consisted of individuals with acute hospitalizations in a geriatric ward, was less mobile and thus were less likely to suffer from known negative effects of OH, such as falls.

The results of the present study contradict, in part, the findings of Weiss et al.\(^{24}\) We did not find any differences in the number of falls or risk factors for falls between the OHP and OHN groups over the year before the assessment. The results of 6 of the 9 studies that were included in the meta-analysis by Angelousi et al\(^{21}\) also did not find any association between OH and risk of falls.

Thus, in the effort to explain the differences in the results of studies on the effect of OH on mortality in different age groups and with varying burdens of morbidity, we side with the assumptions of Masaki et al,\(^1\) Verwoert et al,\(^{22}\) and Rose et al\(^{21}\) that the finding of OH in younger patients is, probably, a manifestation of latent cardiovascular disease or autonomic dysfunction that has not been expressed clinically yet, and in older patients it is a manifestation of frailty. In frail elderly patients with a heavy burden of disease OH may affect mortality through classic risk factors, but it cannot be isolated as a significant independent risk factor.

In the present study, older age was an independent risk factor for overall mortality. Similar results were found in most previous studies.\(^{13,24,25}\) When specific diseases that were associated with increased overall mortality in univariate analyses were entered into the Cox model, no specific disease still had a statistically significant association with increased mortality. The lack of significant association for the other diseases would appear to stem from the small sample of patients who suffered from specific diseases. Nevertheless, when a more comprehensive index of morbidity, CCI-TS, was entered into the model it was found to be a significant, independent predictor of overall mortality (HR = 1.21; 95% CI: 1.11–1.33).

**Strengths and Limitations of the Study**

The study has several advantages. To our knowledge, this is the first study that assessed possible associations between overall mortality and OH in a population of frail elderly patients who came for a comprehensive geriatric assessment. The study population was well defined and there was a complete database on overall mortality. In multivariate analysis, we used the CCI, thus reducing the risk that some comorbidities were missed. And, finally, in present study, the same nurse conducted blood pressure measurements using 1 protocol throughout the study.

This study also has several limitations. First, as a retrospective study, its results are very dependent on the inclusiveness of the medical records. Thus, for example, there was insufficient data for 95 of the 571 patients (16.6%) to calculate the CCI-TS, which could lead to biased results. Second, the study was conducted in 1 center only and with a relatively small number of participants. The patient population that came to the unit for geriatric assessment may be different from the general population of frail elderly, especially because these specific patients were referred for comprehensive geriatric assessment. Thus, the results of this study may not be generalizable to the overall population of frail elderly. In addition, we only analyzed overall mortality because we did not have access to cause-specific mortality. Another possible limitation of this study is that blood pressure measurements were conducted at 1 time only. The medical literature indicates that the reproducibility of OH is low and that OH varies over the course of the day.\(^78–32\) Nevertheless, Hossain et al\(^{32}\) found that mortality was the same in patients with OHS when OH was assessed at 1 time only compared with those with more than 1 OH measurement. Thus, we believe that this limitation does not have a critical effect on the results of the study. And, finally, it is possible that the geriatric assessment process in the unit may, per se, change mortality and could be a significant confounder. However, the results of 2 systematic reviews did not show that outpatient comprehensive geriatric assessment affects mortality.\(^33,34\)

In conclusion, we found that OH is not an independent risk factor for overall mortality. In frail elderly population, OH is most likely a marker of frailty that is easy to measure.

**REFERENCES**

1. Masaki KH, Schatz UJ, Burchfiel CM, et al. Orthostatic hypotension predicts mortality in elderly men: the Honolulu Heart Program. *Circulation.* 1998;98:2290–2295.

2. Poon IO, Braun U. High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. *J Clin Pharmacol.* 2005;30:173–178.

3. Ensrud KE, Nevitt MC, Yunits C, et al. Postural hypotension and postural dizziness in elderly women. The study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. *Arch Intern Med.* 1992;152:1058–1064.

4. Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. *Am J Med.* 2000;108:106–111.

5. Rose KM, Tyrooler HA, Nardo CJ, et al. Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in Communities study. *Am J Hypertens.* 2000;13 (6 pt 1):571–578.

6. Fedorowski A, Stavenow L, Hedblad B, et al. Orthostatic hypotension predicts all-cause mortality and coronary events in middle-aged individuals (The Malmo Preventive Project). *Eur Heart J.* 2010;31:85–91.

7. Fedorowski A, Hedblad B, Engstrom G, et al. Orthostatic hypotension and long-term incidence of atrial fibrillation: the Malmo Preventive Project. *J Intern Med.* 2010;268:383–389.

8. Agarwal SK, Alonso A, Whelton SP, et al. Orthostatic change in blood pressure and incidence of atrial fibrillation: results from a bi-ethnic population based study. *PloS One.* 2013;8:e79030.

9. Xin W, Lin Z, Li X. Orthostatic hypotension and the risk of congestive heart failure: a meta-analysis of prospective cohort studies. *PloS One.* 2013;8:e63169.

10. Fedorowski A, Engstrom G, Hedblad B, et al. Orthostatic hypotension predicts incidence of heart failure: the Malmo preventive project. *Am J Hypertens.* 2010;23:1209–1215.

11. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987–1996. *Stroke.* 2000;31:2307–2313.

12. Angelousi A, Girerd N, Benetos A, et al. Association between orthostatic hypotension and cardiovascular risk, cerebrovascular risk, cognitive decline and falls as well as overall mortality: a systematic review and meta-analysis. *J Hypertens.* 2014;32:1562–1571.

13. Xin W, Lin Z, Mi S. Orthostatic hypotension and mortality risk: a meta-analysis of cohort studies. *Heart.* 2014;100:406–413.

14. Press Y, Peleg R, Dwolatzky T. Five years experience at a community-based comprehensive geriatric assessment unit in southern Israel. *Harefuah.* 2012;151:505–51058.
15. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Neurol Sci. 1996;144:218–219.

16. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.

17. Doble SE, Fisher AG. The dimensionality and validity of the Older Americans Resources and Services (OARS) Activities of Daily Living (ADL) Scale. J Outcome Meas. 1998;2:4–24.

18. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J. 1965;14:61–65.

19. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.

20. Luukinen H, Koski K, Laippala P, et al. Prognosis of diastolic and systolic orthostatic hypotension in older persons. Arch Intern Med. 1999;159:273–280.

21. Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 2006;114:340–346.

22. Verwoert GC, Mattace-Raso FU, Hofman A, et al. Orthostatic hypotension and risk of cardiovascular disease in elderly people: the Rotterdam study. J Am Geriatr Soc. 2008;56:1816–1820.

23. Fisher AA, Davis MW, Srikusalanukul W, et al. Postprandial hypotension predicts all-cause mortality in older, low-level care residents. J Am Geriatr Soc. 2005;53:1313–1320.

24. Weiss A, Belooseisky Y, Kornowski R, et al. Influence of orthostatic hypotension on mortality among patients discharged from an acute geriatric ward. J Gen Intern Med. 2006;21:602–606.

25. Lagro J, Laurensen NC, Schalk BW, et al. Diastolic blood pressure drop after standing as a clinical sign for increased mortality in older falls clinic patients. J Hypertens. 2012;30:1195–1202.

26. Luukinen H, Airaksinen KE. Orthostatic hypotension predicts vascular death in older diabetic patients. Diabetes Res Clin Pract. 2005;67:163–166.

27. Davis BR, Langford HG, Blaufox MD, et al. The association of postural changes in systolic blood pressure and mortality in persons with hypertension: the Hypertension Detection and Follow-up Program experience. Circulation. 1987;75:340–346.

28. Weiss A, Grossman E, Beloosesky Y, et al. Orthostatic hypotension in acute geriatric ward: is it a consistent finding? Arch Intern Med. 2002;162:2369–2374.

29. Ward C, Kenny RA. Reproducibility of orthostatic hypotension in symptomatic elderly. Am J Med. 1996;100:418–422.

30. Alli C, Avanzini F, Bettelli G, et al. Prevalence and variability of orthostatic hypotension in the elderly. Results of the ‘Italian study on blood pressure in the elderly (SPAA)’. The ‘Gruppo di Studio Sulla Pressione Arteriosa nell’Anziano’. Eur Heart J. 1992;13:178–182.

31. Lipsitz LA, Storch HA, Minaker KL, et al. Intra-individual variability in postural blood pressure in the elderly. Clin Sci (Lond). 1985;69:337–341.

32. Hossain M, Ooi WL, Lipsitz LA. Intra-individual postural blood pressure variability and stroke in elderly nursing home residents. J Clin Epidemiol. 2001;54:488–494.

33. Kuo HK, Scandrett KG, Dave J, et al. The influence of outpatient comprehensive geriatric assessment on survival: a meta-analysis. Arch Gerontol Geriatr. 2004;39:245–254.

34. Stuck AE, Siu AL, Wieland GD, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1995;342:1032–1036.